New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration.

New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration.
复制标题

DOI:
10.1155/2012/637316
复制
发表时间:
2012
影响因子:
1.9
通讯作者:
Roh YJ
Roh YJ
中科院分区:
医学4区
文献类型:
--
作者:
Park YG;Rhu HW;Kang S;Roh YJ

文献摘要

参考文献

被引文献

相似文献

视网膜相关性黄斑变性(AMD)是老年人视力丧失的主要原因。血管生成是与AMD引起的CNV发展相关的重要因素。用玻璃体内抗VEGF单一疗法治疗CNV是目前的护理标准。然而,并非所有患者均对单药治疗有反应,改良的抗VEGF治疗方案和联合治疗可能以降低治疗频率或改善视力结果为目标。本文回顾了许多临床试验,已进行利用几种治疗方案。虽然许多试验表明这种可变疗法是合理的,但需要进一步研究以确定正确的方案和剂量。
Age-related macular degeneration (AMD) is the leading cause of visual loss in older population. Angiogenesis is an important factor associated with the development of CNV due to AMD. Treatment of CNV with intravitreal anti-VEGF monotherapy is currently the standard of care. However, not all patients respond to monotherapy, and modified anti-VEGF treatment regimen and combination therapy may target reducing treatment frequency or improving visual outcome. This paper reviews the many clinical trials that have been performed utilizing several treatment regimens. While many trials have shown that this variable therapy is justifiable, further study is required to determine correct regimens and dosage.
DOI: 10.1016/j.ophtha.2009.05.033
发表时间: 2009-09-01
期刊: OPHTHALMOLOGY
影响因子: 13.7
作者:
Dadgostar, Hajir;Ventura, Alexandre A. C. M.;Kaiser, Peter K.
通讯作者: Kaiser, Peter K.
DOI: 10.1016/j.ophtha.2007.04.030
发表时间: 2007-10-01
期刊: OPHTHALMOLOGY
影响因子: 13.7
作者:
Kaiser, Peter K.;Blodi, Barbara A.;Acharya, Nisha R.
通讯作者: Acharya, Nisha R.
DOI: 10.1056/nejmoa062655
发表时间: 2006-10-05
影响因子: 158.5
作者:
Brown, David M.;Kaiser, Peter K.;Schneider, Susan
通讯作者: Schneider, Susan
DOI: 10.1016/j.ophtha.2009.05.024
发表时间: 2009-09-01
期刊: OPHTHALMOLOGY
影响因子: 13.7
作者:
Boyer, David S.;Heier, Jeffrey S.;Rubio, Roman G.
通讯作者: Rubio, Roman G.
DOI: 10.1056/nejmoa042760
发表时间: 2004-12-30
影响因子: 158.5
作者:
Gragoudas, ES;Adamis, AP;Guyer, DR
通讯作者: Guyer, DR